October 17, 2023

1. Introduction Renal cell carcinoma is one of the most common malignancies of urinary tract. Metastatic disease on index presentation is quite commonly seen. Nearly 40% of patients will develop metastases after nephrectomy, and about 10% will be diagnosed with late metastatic disease after 5 years [1]. Most metastases are located in the lungs (75%), lymph nodes (36%), bone (20%) or liver (18%) [2]. Gastrointestinal tract is very unusual location for RCC metastases.

1. Abstract Immunotherapy has a cardinal role in renal cancer, both in adju- vant setting and metastatic disease (first or subsequent lines). Se- vere immune-related adverse events (irAEs) occur in 10-27% of patients treated with immunotherapy [1,2], but the discontinuation of the treatment due to toxicity doesn’t necessarily correlate with poor outcome.